We then selected Cetuximab, an anti-EGFR antibody approved for the clinical treatment of HNSCC, combined with CYH33 to evaluate the efficacy against HNSCC in vivo. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.